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Barrier-to-autointegration factor 1 (Banf1) regulates
poly [ADP-ribose] polymerase 1 (PARP1) activity
following oxidative DNA damage
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The DNA repair capacity of human cells declines with age, in a process that is not clearly
understood. Mutation of the nuclear envelope protein barrier-to-autointegration factor 1
(Banf1) has previously been shown to cause a human progeroid disorder, Néstor–Guillermo
progeria syndrome (NGPS). The underlying links between Banf1, DNA repair and the ageing
process are unknown. Here, we report that Banf1 controls the DNA damage response to
oxidative stress via regulation of poly [ADP-ribose] polymerase 1 (PARP1). Speciﬁcally,
oxidative lesions promote direct binding of Banf1 to PARP1, a critical NAD+-dependent DNA
repair protein, leading to inhibition of PARP1 auto-ADP-ribosylation and defective repair of
oxidative lesions, in cells with increased Banf1. Consistent with this, cells from patients with
NGPS have defective PARP1 activity and impaired repair of oxidative lesions. These data
support a model whereby Banf1 is crucial to reset oxidative-stress-induced PARP1 activity.
Together, these data offer insight into Banf1-regulated, PARP1-directed repair of oxidative
lesions.
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During the ageing process DNA repair mechanisms dete-riorate, leading to the accumulation of DNA damage,contributing toward the development of ageing-associated
diseases, such as cancer, osteoporosis and Alzheimer’s disease1–4.
Barrier-to-autointegration factor 1 (Banf1) is a DNA-binding
protein that functions to tether DNA to structural proteins
located on the nuclear envelope5. Strikingly, a point mutation in
Banf1, alanine 12 to threonine (A12T), is associated with a severe
premature ageing syndrome, Néstor–Guillermo progeria syn-
drome (NGPS), characterised by pathologies usually associated
with ageing, such as generalised lipoatrophy and severe
osteoporosis6,7. Premature ageing is intrinsically linked with
genome stability. For example, the genes mutated in other well-
characterised progeria syndromes such as Werner Syndrome and
Hutchinson–Gilford (Progeria) Syndrome result from mutations
in WRN and Lamin A genes, respectively and are implicated in
DNA repair and genome stability1,8.
The poly [ADP-ribose] (PAR) polymerase 1 (PARP1) protein
responds rapidly to DNA strand breaks and oxidative DNA
damage, using NAD+ to catalyse auto-ADP-ribosylation, adding
long, branched PAR chains up to 200 residues in size onto serine
and glutamic residues in the PARP1 automodiﬁcation domain9–14.
These serve to further activate PARP1, promoting the recruitment
of other DNA repair proteins involved in the repair process,
including XRCC1 (X-ray repair cross-complementing protein 1),
and DNA end-processing kinase/phosphatase PNK (bifunctional
polynucleotide phosphatase/kinase)15. Many PARP1 substrates
have been identiﬁed, including targets with roles in DNA repair,
transcription and regulation of chromatin structure. Recent stu-
dies have identiﬁed that in addition to glutamic residues,
PARP1 substrates may also be ADP-ribosylated on serine or tyr-
osine residues9–14,16. The catalytic domain of PARP1 is respon-
sible for three enzymatic reactions during synthesis of the PAR
chains, initiation, elongation and branching.
Increased PARP1 activity has been shown to be associated with
improved health and longevity17–19. Thus, increasing our under-
standing of PARP1 regulation is of critical importance and has
implications for ageing-associated diseases such as cancer20,21.
We present here evidence that Banf1 functions in DNA repair
and genome stability pathways through the direct regulation of
PARP1 poly-ADP-ribose polymerase activity. Speciﬁcally, Banf1
relocalises from the nuclear envelope following oxidative stress
and binds directly to PARP1 to inhibit auto-poly-ADP-ribose
activity. In addition, we also show that mutation of Banf1 in a
human progeria syndrome impacts upon PARP1 activity and
subsequent DNA repair.
Results
Banf1 responds to oxidative stress. One of the main character-
istics of proteins that are mutated in premature ageing syndromes
is that they are involved in the repair of DNA damage8. Given
that mutation of Banf1 leads to a premature ageing syndrome, we
reasoned that Banf1 may also play a role in the repair of DNA
damage. In unperturbed cells, Banf1 can be detected in pre-
extracted cells, to be localised to the nuclear envelope5. However,
following induction of oxidative stress by H2O2, that primarily
induces oxidised DNA bases in the form of 8-Oxo-Guanine (8-
OxoG) lesions22, Banf1 relocalised from the nuclear envelope to
the chromatin between 1- and 2-h post H2O2 removal (Fig. 1a, b).
This was not due to nuclear envelope breakdown as the Banf1-
interacting protein Emerin (EMD) remained on the nuclear
envelope following H2O2 treatment (Fig. 1a). This response to
H2O2 was compared to another oxidising agent, that also pri-
marily induces 8-OxoG lesions23, potassium bromate (KBrO3)
and the topoisomerase I inhibitor, camptothecin (CPT). Banf1
was observed to respond similarly to H2O2, KBrO3 and CPT and
could not be detected on the nuclear envelope within 2 h of
treatment (Fig. 1c, d). CPT initially induces single-strand DNA
breaks that are processed into double-strand breaks during the S-
phase of the cell cycle24. Notably, Banf1 relocalised from the
nuclear envelope within 2 h of camptothecin treatment in the
majority of cells, indicating this was not solely an S-phase or
DNA double-strand break response (as marked by γ-H2AX),
suggesting that in contrast to γ-H2AX Banf1 may respond to
DNA single-strand breaks, before they are converted to double-
strand breaks in S-phase (Supplementary Fig. 1a, b). Images of
cells ﬁxed without prior treatment with extraction buffer have
been included as a comparison for Banf1 localisation in soluble
fractions and illustrates that relocalisation of Banf1 can not be
detected in cells that have not been treated with extraction buffer
(Supplementary Fig. 1c). Banf1 can be detected in both the
cytoplasmic and chromatin-bound fractions in unperturbed cells
and H2O2 treatment induces increases in Banf1 protein levels in
the chromatin fraction and total cell lysates following H2O2
treatment (Supplementary Fig. 1d, e).
Banf1 interacts with PARP1. Given that the Banf1 protein
responded to oxidative stress and single-strand breaks, we next
reasoned that Banf1 may regulate other proteins involved in these
repair pathways. PARP1 is required for repair of DNA single-
strand breaks and as such is involved in the repair of both oxi-
dative lesions (in which single-strand breaks are produced as a
by-product of base excision repair) and direct single-strand
breaks20. PARP1 has previously been identiﬁed as a Banf1
interactor in a large-scale proteomics screen25. We demonstrated
an interaction between Banf1 and PARP1 in human embryonic
kidney (HEK) 293T cells expressing Flag-Banf1 or Flag-PARP1
(Fig. 2a, b) and also between endogenous proteins in 293T cells
and human skin ﬁbroblasts, conﬁrming that Banf1 and PARP1
form a complex (Supplementary Fig. 2a, b). Furthermore, this
interaction was increased by H2O2-induced oxidative stress
(Fig. 2c, Supplementary Fig. 2b, c). The interaction was shown to
be direct and remained intact in the absence of NAD+ and DNA,
in the presence of PARP1 inhibitors and when PARP1 was cat-
alytically inactive (PARP1 E988K) in vitro and in cells (Fig. 2d,
Supplementary Fig. 2d–f), suggesting the binding is independent
of Poly-ADP-ribose activity. Consistent with the interaction
between Banf1 and PARP1 following oxidative DNA damage, we
could also observe their colocalisation via immunoﬂuorescence
(Fig. 2e). The Pearson coefﬁcient r values were 0.24, prior to
H2O2 and 0.38 and 0.48, 0.5 h and 1 h following removal of H2O2,
respectively.
Banf1 regulates PARP1 poly-ADP-ribose activity. We next
examined the effect of Banf1 on PARP1 activity. Cells depleted of
Banf1 demonstrated increased PARP1 auto-ADP-ribosylation
activity following H2O2 treatment (Fig. 3a, Supplementary Fig. 3a,
b). Conversely, ectopic overexpression of Banf1, reproducibly
decreased PARP1 auto-ADP-ribosylation, suggesting that Banf1
negatively regulates PARP1 activity (Fig. 3b). This effect was also
observed in vitro (Supplementary Fig. 3c). Consistent with the
defect in auto-ADP-ribosylation, PARP1 activity towards histones
was signiﬁcantly inhibited in the presence of Banf1 (Fig. 3c).
Similarly, the direct ADP-ribosylation of histones H3/H4 was also
signiﬁcantly inhibited by Banf1 in a reconstituted assay (Fig. 3d).
Following DNA damage poly-ADP-ribosylation is rapidly
removed by the poly-ADP-glycohydrolase, PARG. Treatment of
cells overexpressing Banf1 with a PARG inhibitor was unable
to correct PARP1 ADP-ribosylation to the same extent as
control cells, suggesting that the effect of Banf1 on PARP1
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ADP-ribosylation was not due to upregulation of poly-ADP-
ribose removal by PARG (Supplementary Fig. 3d).
Despite co-localising on the chromatin following H2O2, Banf1
and PARP1 recruitment to chromatin were mutually independent
(Supplementary Fig. 4a, d) and both chromatin-bound Banf1 and
PARP1 levels were similar in cells depleted of the other protein
before and after H2O2 (Supplementary Fig. 4b, c).
Banf1 regulates the repair of oxidative lesions. Depletion of
Banf1 led to a small decrease in H2O2-induced comet tail length
under alkaline conditions, but this did not reach statistical sig-
niﬁcance (Fig. 3e, Supplementary Fig. 4e). In contrast, over-
expression of Banf1 resulted in an increase of H2O2-induced
comet tail length, indicating that the repair of oxidised DNA
lesions was impaired, consistent with the inhibition of PARP1
activity in cells over-expressing Banf1 (Fig. 3f, Supplementary
Fig. 4f).
Banf1 interacts with the NAD+-binding domain of PARP1. In
order to shed light on the mechanism of Banf1-mediated
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Fig. 1 Banf1 responds to oxidative stress. a Banf1 relocalises from the nuclear envelope following oxidative stress induced by 200 μM H2O2 in U2OS cells.
Representative cells are shown. b The nuclear intensity of Banf1 in U2OS cells treated as in (a), were analysed via an InCell Analyser 2200. One-way
ANOVA was used for statistical analysis. c Banf1 relocalisation following hydrogen peroxide (H2O2), camptothecin (CPT), or potassium bromate (KBrO3)
at the indicated times post compound removal. Representative cells stained with the indicated antibodies are shown. d Nuclear envelope localisation (from
(c)) was assessed using a delta vision PDV microscope. Immunoﬂuorescence scale bars represents 10 μm. Histogram data shown represent the mean and
S.D. of three independent experiments. ANOVA **P < 0.01, ***P < 0.001. Source data are provided as a Source Data ﬁle.
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regulation of PARP1 poly-ADP-ribosylation, we next char-
acterised the PARP1–Banf1 interaction, by modelling of protein:
protein interactions using molecular docking. This indicated that
the N-terminus of the Banf1 monomer bound adjacent to the
NAD+ binding site of PARP1 (Fig. 4a, b). The surface contacts of
this PARP1–Banf1 complex were analysed further and the
interaction surface showed good surface complementarity with
numerous interacting residues (Fig. 4b). The PARP1–Banf1
complex was stable during the 100 ns molecular dynamics (MD)
simulation. To predict the effect of Banf1 binding on PARP1
activity, we also superimposed Banf1 onto a model of full-length
PARP1 to examine the ADP-ribosylation sites in the PARP1
auto-modiﬁcation domain (Supplementary Fig. 5). The three
ADP-ribosylation sites (D387, E488 and E491) previously iden-
tiﬁed in the automodiﬁcation domain13 and conserved glutamic
residues E407, E448, E456 and E471 of the single BRCT domain
are in close vicinity to the Banf1 dimer. However, it should also
be noted that serine residues have also been recently identiﬁed as
ADP-ribosylation sites on PARP1 substrates and upon PARP1
itself, in the presence of the PARP1-interacting protein HPF1
(refs 9–12). Three serine residues, S499, S507 and S519 have been
conﬁrmed to be sites of auto-ADP-ribosylatyion, within the
PARP1 automodiﬁcation domain close to the unstructured BRCT
domain10 and the Banf1 dimer is also predicted to bind in close
proximity to these residues.
In order to investigate whether Banf1 binds to the NAD+-
binding domain, as suggested by the modelling, a Flag-PARP1
construct was made with mutations in the residues predicted to
interact with Banf1 and that comprise part of the NAD+ binding
domain, 906–911A. As predicted, mutation of PARP1 906–911A
severely impacted the interaction with endogenous Banf1 protein
(Fig. 4c). The model also predicted that one side of the Banf1
dimer interacted with the BRCT domain of PARP1 and in
support of this, deletion of the BRCT domain completely
inhibited the interaction between Banf1 and PARP1 (Fig. 4d).
Taking into account the modelling predictions, we next made
Flag-Banf1 mutations of D9A and also of two other acidic
residues not implicated in binding. As predicted mutation of
aspartic acid residue 9 to alanine (D9A) disrupted the Banf1:
PARP1 interaction (Fig. 4e, f) but mutation of other acidic
residues did not, unless in combination with D9A (Fig. 4e). As
expected, ectopic expression of wild type Banf1 caused suppres-
sion of PARP1 auto-ADP-ribosylation, while expression of the
Banf1 D9A mutant, that displays reduced binding to PARP1,
failed to inhibit PARP1 auto-ADP-ribosylation (Fig. 4e, g). This
was shown not be due to D9A mislocalisation, as D9A
was observed to localise similarly to wild-type Banf1 before and
after H2O2 (Supplementary Fig. 6a, b). These data suggest that
Banf1 binds to PARP1 directly and functions to inhibit PARP1
activity.
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Since our modelling and mutagenesis data suggested that Banf1
binding may block the entry of NAD+ into the binding pocket of
PARP1, we investigated this possibility further in vitro. To study
the effect of NAD+ binding the well-characterised PARP1 E988K
mutant was used, which has ~1% of the poly-ADP-ribose activity
of wild type PARP1 without affecting NAD+ binding26,27 and
showed no detectable auto-ADP-ribosylation activity in our
studies (also observed in Fig. 2d). The presence of Banf1 was able
to signiﬁcantly inhibit the binding of both biotinylated (Fig. 4h
and Supplementary Fig. 6c, d) and P32 labelled NAD+ to PARP1
(Supplementary Fig. 6e), supporting the prediction that Banf1:
PARP1 binding inhibits NAD+ binding. In support of this the
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D9A Banf1 mutant, that displayed reduced binding to PARP1,
was unable to block NAD+ binding to the same extent as wild-
type Banf1 (Supplementary Fig. 6f).
Mutation of Banf1 A12T inhibits PARP1 activity. A single
homozygous point mutation of Banf1 alanine 12 to threonine
(A12T) leads to the premature ageing syndrome, Néstor–
Guillermo progeria syndrome (NGPS)6,7. It was originally
asserted that mutation of Banf1 A12T destabilised the Banf1
protein7, but we subsequently demonstrated that the A12T
mutated Banf1 was stable, and that the mutation reduced the
antigenicity of the Banf1 antibody against Banf1, disrupting
detection28. The original antibody was raised against the N-
terminal of Banf1, however, a commercially available Banf1
antibody raised against the C-terminal of the Banf1 protein
detects exogenous expression of mutant A12T protein (Supple-
mentary Fig. 7a, b). This C-terminal Banf1 antibody also detected
expression of the mutant protein within the NGPS patient cells,
including Banf1 localisation to the nuclear envelope (Supple-
mentary Fig. 7c, d). This is signiﬁcant as the Banf1 A12T mutant
protein is expressed to similar levels in patient cells as wild-type
Banf1 in normal cells, suggesting that it is the presence of the
mutant protein that causes the pathology of the NGPS premature
ageing syndrome and not the lack of Banf1 protein.
Signiﬁcantly, in contrast to wild type Banf1, the Banf1 A12T
mutant protein was found to interact with PARP1 to the maximal
amount in the absence of DNA damage (Fig. 5a, Supplementary
Fig. 7e). Banf1 A12T was localised to chromatin, similarly to
wild-type Banf1 before and after H2O2 (Supplementary Fig. 7f, g).
It was also observed that puriﬁed Banf1 A12T displayed increased
binding to PARP1 compared to wild-type Banf1 in in vitro
pulldowns (Fig. 5b). The increased interaction in vitro suggests
that the increased interaction was probably not due to an increase
in DNA damage in A12T expressing cells but was more likely due
to a structural change in Banf1 promoting an interaction with
PARP1. Consistently, expression of Banf1 A12T signiﬁcantly
reduced the auto-ADP-ribosylation of PARP1 in vivo (Fig. 5c, d)
and in vitro histone H3/H4 assays (Fig. 5e, f).
Repair of oxidative lesions is disrupted in patients with NGPS.
To assess the impact of A12T mutation on repair of oxidative
lesions we carried out an alkaline comet assay. A12T expression
was found to inhibit DNA repair of oxidative lesions to a similar
extent as overexpression of wild-type Banf1 (Fig. 5g, Supple-
mentary Fig. 8a). We next obtained two NGPS (Banf1 A12T
mutant) patient skin ﬁbroblast cell lines and measured the
PARP1 activity in these cell lines. Following oxidative stress
PARP1 activity on an immobilised histone substrate was sig-
niﬁcantly reduced in NGPS cells compared to wild-type cells
(Fig. 5h). Both patient cell lines also exhibited defective DNA
repair of oxidative lesions as measured by alkaline comet assay
(Fig. 5i, Supplementary Fig. 8b). To assess whether the oxidative
DNA damage repair defect in the NGPS cell lines was caused by
the presence of the Banf1 A12T protein we depleted Banf1 from
NGPS patient cells and control cells and carried out comet assay
analysis. This conﬁrmed that depletion of Banf1 A12T protein in
both NGPS patient cell lines was sufﬁcient to restore repair of
oxidative lesions, comparable to control cells (Supplementary
Fig. 8c–e). The defective oxidative DNA repair observed in the
NGPS patient cells was comparable to a partial depletion of
PARP1 protein in control cells. Whereas, expression of a cata-
lytically inactive PARP1 E988K mutant led to a greater repair
defect (Supplementary Fig. 8f–h).
Despite binding more robustly, Banf1 A12T was not able to
block NAD+ binding more efﬁciently than wild-type Banf1
(Supplementary Fig. 9a), suggesting that the greater inhibition of
PARP1 in cells expressing A12T is likely due to another
mechanism. In support of this, our modelling studies were
unable to detect any difference between WT and A12T: PARP1
binding, with both proteins appearing to bind with similar
afﬁnities. In the absence of a higher resolution three-dimensional
structure of Banf1:PARP1, we hypothesise that the ﬂexible and
disordered BRCT-WGR linker of PARP1 might be allosterically
modulating protein-protein interactions with one of the mono-
mers of the Banf1 dimer and that A12T may further promote this
interaction, leading to inhibition of PARP1 auto-poly-ADP-
ribosylation.
PARP1 protein levels were comparable to control cells in the
NGPS patient cells (Supplementary Fig. 9b). PARP1 recruitment
following H2O2 observed in NGPS cells and cells expressing
ectopic A12T was comparable to that in wild type cells
(Supplementary Fig. 9c, d) and PARP1 was observed to colocalise
with ectopically expressed Banf1 A12T (Supplementary Fig. 9d).
The poly-ADP-ribose activity of PARP1 is dependent upon
NAD+, but the decreased oxidative stress-induced PARP1
activity observed in NGPS cells was not due to lower NAD+
levels as NAD+ levels were shown to be increased in these cells
(Supplementary Fig. 10a). In contrast NAD+ levels were
signiﬁcantly decreased in Banf1-depleted cell lines (Supplemen-
tary Fig. 10b).
Discussion
There have been signiﬁcant advances in our understanding of
PARP1 structure and function in recent years, however, the
regulatory mechanisms governing PARP1 activity are still largely
unknown. The data presented here deﬁne a direct role for Banf1
in the regulation of PARP1 ADP-ribose activity.
Here, we have characterised the response of the nuclear
envelope protein Banf1 to oxidative stress, which promotes its
relocalisation from the nuclear envelope to colocalise with and
bind to PARP1. Banf1 binds to the NAD+ binding domain of
PARP1 and is able to block NAD+ from entering the NAD+
Fig. 3 Banf1 regulates PARP1 activity and repair of oxidative DNA damage. a Auto-poly-ADP-ribosylation of PARP1 in U2OS cells depleted of Banf1 following
H2O2. The PAR bands were analysed via densitometry and normalised to γ-Tubulin. Two-way ANOVA was used for statistical analysis. b Auto-poly-ADP-
ribose of PARP1 in U2OS expressing ectopic Flag-Banf1 following H2O2. The PAR bands were analysed via densitometry and normalised to γ-Tubulin. Two-
way ANOVA was used for statistical analysis. c Inhibition of poly-ADP-ribose activity of PARP1 puriﬁed from HEK293T cells expressing ectopic Flag-Banf1
on an immobilised histone substrate following H2O2. Data shown represent the mean and S.D. of two independent experiments. Paired t-test was used for
statistical analysis. d In vitro inhibition of PARP1 poly-ADP-ribose activity on histones by puriﬁed Banf1. e Alkaline comet assay showing the relative olive
tail moment in Banf1-deﬁcient and control U2OS cells. f Banf1 inhibits repair of oxidative DNA damage. Alkaline comet assay showing the relative olive tail
moment in U2OS control cells and cells ectopically expressing Flag-Banf1. Paired t test was used for statistical analysis. Histogram data shown in
f represent the mean and S.D. of four independent experiments immunoblots are representative of three independent experiments. Unless otherwise
stated, histogram data shown represent the mean and S.D. of three independent experiments. ANOVA was used for statistical analysis. *P < 0.05, **P <
0.01. Source data are provided as a Source Data ﬁle.
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binding domain of PARP1, preventing PARP1 poly-ADP-ribose
activity.
In recent years, several PARP1 regulatory proteins have been
identiﬁed, including SAM68, HPF1 and YB-1 (refs 14,29–31). To
the best of our knowledge, all of the known PARP1 regulatory
proteins stimulate the activity of PARP1, with the exception of
poly-(ADP-ribose) glycohydrolase (PARG)32, which removes
the poly-ADP-ribose chains from PARP1 and its substrates. In
contrast, Banf1 is the ﬁrst identiﬁed PARP1 regulatory protein to
directly inhibit PARP1 activity via binding to its NAD+ binding
domain to block substrate binding.
We envision two possible mechanisms for increased binding of
A12T Banf1 to PARP1. We have previously shown using mod-
elling, CD spectra and EMSA studies that A12T mutant does not
induce secondary structure change but causes only minor rear-
rangement of the side-chains disrupting the interaction of Banf1
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Fig. 4 The N-terminal of Banf1 binds to the NAD-binding domain of PARP1. a Structural superimposition of catalytic domains of chicken (blue colour) and
human (golden colour) PARP1. NAD+ analogue is shown as ball and sticks and the conserved binding site residues shown as sticks. The loop consisting of
residues 906–911 and 883–893 of PARP1 are highlighted in dark green and orange, respectively. b 3D structure of the most representative catalytic domain
of PARP1–Banf1 obtained from Cluspro docking server. The Banf1 dimer is shown in red and green ribbons. The N-terminal of Banf1 monomer occupies the
NAD+ binding site hence inhibiting NAD+ interaction. The interface residues and interactions at the PARP1–Banf1 interface are shown in the box where
chain A and C represents residues from PARP1 and Banf1, respectively. The loop consisting of residues 906–911 of PARP1 are highlighted in dark green.
Single-letter abbreviations for the amino acid residues are as follows: A, Ala; E, Glu, D, Asp; N, Asn. c, d Interactions of Banf1 with Flag-PARP1 mutants. Flag
immunoprecipitations from HEK293T cells ectopically expressing the indicated Flag-PARP1 proteins 1 h following H2O2 removal. e Interactions of PARP1
with Flag-Banf1 mutants. Flag immunoprecipitations from HEK293T cells ectopically expressing the indicated Flag-Banf1 proteins 1 h following H2O2
removal. f Analysis of the relative Banf1 WT vs. D9A binding to PARP1 via immunoprecipitation. g Analysis of the relative auto-poly-ADP-ribosylation of
PARP1 in cells expressing WT or D9A Banf1. h In vitro inhibition of PARP1 binding NAD+ in the presence of puriﬁed Banf1. Histogram data shown in h,
represent the mean and S.D. of four independent experiments. Immunoblots are representative of three independent experiments. Unless otherwise stated,
histogram data shown represent the mean and S.D. of three independent experiments. Unpaired t test was used for statistical analysis. *P < 0.05, **P <
0.01, ***P < 0.001. Source data are provided as a Source Data ﬁle.
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with DNA, in agreement with the current experimental data28. In
the ﬁrst mechanism, as we have shown previously the Banf1
A12T protein is impaired in its ability to bind DNA and since the
DNA-binding site and PARP1 binding site within Banf1 share
overlapping residues it seems likely that Banf1 A12T would be
more available to bind to PARP1 than wild-type Banf1, since a
proportion of wild-type Banf1 would also be bound to DNA.
However, this model only explains the increased binding in part
and does not offer an explanation for the increased binding of
Banf1 A12T to PARP1 in vitro, in the absence of DNA.
The second mechanism is based on the molecular model where
the NAD+ and Banf1 sites within PARP1 are partially over-
lapping. While the small molecules like NAD+ or its benzamide
analogues could access both the nicotinamide and the deeper
adenosine pocket in an open, unfolded helical subdomain (HD)
conformation33,34, our study indicates that a macromolecule like
Banf1 could only access the nicotinamide binding site. This is
supported by our data showing that Banf1 partially blocks NAD+
binding to PARP1, but does not completely inhibit it.
We are unable to accurately model the side of the Banf1 dimer,
which is involved in binding to PARP1 around the BRCT domain,
as this region of PARP1 is unstructured/ﬂexible and the current
models available cannot account for the localisation/structure of
this region. Since Banf1 A12T did not signiﬁcantly inhibit NAD+
binding to PARP1, we consider it is likely to be the other side of
the Banf1 dimer, that would be in proximity with the BRCT
domain of PARP1, where A12T would be likely to have a stronger
binding and inhibitory effect on PARP1 activity. We anticipate that
Banf1 will act to either directly perturb the HD structure, or alter
the HD structure by engaging the WGR/BRCT domain. Lastly, due
to Banf1 binding in close proximity to the BRCT domain, it could
also directly block the auto-ADP-ribosylation of PARP1 residues,
required for it’s activity. Understanding the exact nature of this
interaction and mechanism will form part of a future study.
PARP1 activity declines with age and its increased expression
has been implicated in improved health and longevity17–19.
Conversely, we also show here that mutation of Banf1 impacts
upon PARP1 activity and repair of oxidative lesions in a human
progeria syndrome, potentially highlighting the signiﬁcance of this
function for human health. Cells from patients with Werner
syndrome and Hutchinson–Guildford progeria also display defects
in PARP1 activity and defective DNA repair35–39. Therefore,
together with the data from NGPS patient cells presented here, it
leads us to speculate that this mechanism may contribute, in part,
to the overlapping pathologies in these progeroid diseases. How-
ever, it is also likely that Banf1 has other uncharacterised roles in
the cell that may also promote NGPS patient phenotypes.
We speculate that similarly to our previous work on DBC1
(ref. 19), the Banf1-dependent regulation of PARP1 forms another
mechanism to enable cellular control of NAD+ concentration,
preventing the hyperactivation of PARP1 and subsequent deple-
tion of NAD+ following DNA damage (Supplementary Fig. 11).
This hypothesis is supported by the higher NAD+ levels observed
in NGPS cells with lower PARP1 activity and lower NAD+ levels
in Banf1 deﬁcient cells with higher PARP1 activity, although it is
important to note that this may not be as a direct result of PARP1
inhibition.
In summary, these data support a model whereby cellular levels
of Banf1 are crucial to reset oxidative-stress-induced PARP1
activity. Together, these data offer insight into the Banf1-regu-
lated, PARP1-directed repair of oxidative lesions.
Methods
Ethics. All experimental procedures were approved by the Queensland University
of Technology; Human Research Ethics Committee (approval numbers
1700000940 and 1900000269).
Cell lines. The U2OS and HEK293T cells were obtained from CellBank Australia
(catalogue numbers 92022711 and 85120602, respectively). U2OS cells were grown
in RPMI media, supplemented with 10% foetal bovine serum (FCS), HEK293T cells
were grown in DMEM media, supplemented with 10% FCS. The NGPS patient
cells and a matched control cell line were a kind gift from Carlos Lopez-Otin and
were established from two different patients with NGPS. The NGPS cells and
control cell line were grown in DMEM high glucose (Invitrogen 41965-062),
supplemented with 10% FCS. Cell lines were grown at 37 °C, 5% CO2 and at
atmospheric O2, unless otherwise stated.
Chemical reagents. All reagents were purchased from Sigma with the following
exceptions; Olaparib was purchased from Selleck Chemicals, Biotinylated NAD+
was from R&D Systems and NAD+ p32 isotope was purchased from Perkin Elmer.
The PARG inhibitor PDD00017273 was used at a concentration of 1 μΜ. The
PARP1 inhibitor, BYK204165 was used at a concentration of 10 μΜ.
Constructs. Myc-DDK-tagged human PARP1 (Flag-PARP1) was purchased from
OriGene (RC207085). The BRCT deletion mutant for Flag-PARP1 were generated
using a Quickchange II XL Site Directed Mutagenesis kit (Stratagene), and veriﬁed
by DNA sequencing. The Flag-Banf1 and Flag-PARP1 mutants were synthesised
and mutated using site-directed mutagenesis by Genscript in the pcDNA3.1+N-
DYK vector in the BamHI-XhoI cloning sites. These constructs were sequenced
using the CMV primer (5′-CGCAAATGGGCGGTAGGCGTG-3′). The His-Banf1
wild-type and mutants were synthesised and mutated by Genscript in the pET-28a
(+) vector in the NdeI-XhoI cloning sites. These constructs were sequenced using
the T7 primer (5′-TAATACGACTCACTATAGG-3′).
Antibodies. The antibodies used were as follows: anti-Banf1 N-terminus
(SAB1409950, Sigma-Aldrich and ab88464, Abcam, 1:1000 for WB and 1:500 for
IF), anti-Banf1 C-terminus (PRS40170604, Sigma-Aldrich, 1:1000 for WB and
1:500 for IF), PARP1 (9532, Cell Signalling Technology 1:1000 for WB and 1:500
for IF), PARP1 (ab191217, Abcam Fig. 2e 1:500 for IF), anti-Emerin (5430, Cell
Signalling Technology, 1:500 for IF), anti-Flag M2 Antibody (F3165, Sigma-
Aldrich, 1:1000 for WB and 1:300 for IF), anti-PAR (ab14459, Abcam, 1:1000 for
WB), anti-γ-Tubulin (T6557, Sigma-Aldrich, 1:2000 for WB), anti-H3 (4499, Cell
Signalling Technology, 1:2000 for WB), anti-H4 (2935 Cell Signalling Technology
1:1000 for WB), anti-SP1 (9389, Cell Signalling Technology, 1:1000 for WB), anti-
EGFR (sc-03, Santa-cruz, 1:500 for WB), anti-LC3B (2775, Cell Signalling Tech-
nologies, 1:1000 for WB), anti-phospho-p53 ser15 (2984, Cell Signalling Tech-
nology, 1:1000 for WB), anti-β-actin (612656, BD Biosciences, 1:2000 for WB).
Fluorescent secondary antibodies used were: Donkey anti-Mouse 800 nm (LiCor;
IRDye 800CW 926-32212, 1:5000 for WB), Donkey anti-Rabbit (LiCor; IRDye
680LT 926-28023, 1:5000 for WB) and Alexa Fluor 488 (Cat# A32766,
Molecular Probes, 1:200 for IF) and 594 (Cat# A32754, Molecular Probes,
1:200 for IF).
siRNA. Control, Banf1 and PARP1 pooled esiRNA were purchased from Sigma.
Control and Banf1 siRNA were purchased from GenePharma (Banf1, GGGUU
UUGACAAGGCCUAUdTdT). Cells were typically assayed 72 h after transfection.
ShRNA generation and transformation. ShRNA sequences (Banf1-1 shRNA:
GGGAATGGCTGAAA, Banf1-2 shRNA GAATGGCTGAAAGACACTT) were
cloned into pLKO.1 (Addgene: 10878) as per Addgene referenced protocol
(pLKO.1 TRC cloning).
The day before transfection (Day 1), 293FT cells were plated into a T75 tissue
culture plate so that they would be 90–95% conﬂuent on the day of transfection.
For each transfection reaction Fugene HD complexes were generated as follows:
36 μl Fugene+ 1.5 ml OptiMEM per reaction then added 0.5 μg pTAT, 2.8 μg
pHEF-VSV-G and 7.1 μg pNHP+ 3.5 μg of Lentiviral Plasmid (pLKO.1 containing
shRNA) per reaction. Complexes were incubated for 15 min and added to each
plate of cells. Incubate the cells overnight at 37 °C in a humidiﬁed 5% CO2
incubator. The next day media was replaced. Virus was harvested after 48/72 h by
collecting the condition media and centrifuging the 293FT cells.
To transform cells: Polybrene (2 μg/mL) was added to plated U2OS cells,
followed by the addition of 1 mL of virus containing media (T25). Cells were
cultured for 48–72 h for optimal depletion of Banf1.
Transfections. All DNA constructs were transfected using Fugene HD (Promega)
as per manufacturer’s instructions. RNAiMax (Invitrogen) was used to transfect
esiRNA and siRNA as per manufacturer’s instructions.
Immunoblotting. Cells were lysed (lysis buffer: 20 mM HEPES pH7.5, 250 mM
KCl, 5% glycerol, 10 mM MgCl2, 0.5% Triton X-100, Protease inhibitor cocktail
(Roche) and phosphatase inhibitor cocktail (Cell Signalling)) and sonicated.
Lysates were cleared by centrifugation. Typically, 30 μg of protein lysate was
separated on a 4–12% sodium dodecyl sulfate (SDS)-polyacrylamide gel electro-
phoresis (Invitrogen) blocked in Odyssey buffer (LiCor Biosciences) and
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immunoblotted with the indicated antibodies. Immunoblots were imaged using an
Odyssey infra-red imaging system (LiCor).
Immunoprecipitation. Cells were treated as stated then lysed and sonicated as for
immunoblotting. Lysates were transferred to a new tube and incubated with Pierce™
Universal Nuclease for Cell Lysis to digest DNA. Digested lysates were then
incubated with the indicated antibodies or equivalent amount of IgG for the
relevant species for 1 h on rotation at 4 °C. Protein A or G magnetic Dynabeads
(Thermoﬁsher) were then added to the tubes and were incubated for 1 h on
rotation at 4 °C. Beads were then washed 5 times in lysis buffer and boiled in 2×
SDS loading dye.
Direct interactions. The puriﬁed wild type PARP1 and PARP1 E988K recombi-
nant proteins were purchased from Sigma and Abcam, respectively. In order to
purify Banf1 recombinant protein, the method was adapted from ref. 28. Plasmids
expressing HexaHis-tagged WT or A12T Banf1 were transformed into BL21 (DE3)
pLys Escherichia coli. E. coli were grown at 37 °C and 1mM IPTG was used to
induce protein expression for 3 h. Following induction, the E. coli were harvested
by centrifugation and stored overnight at −80 °C. Cell pellets were lysed in 8 mL of
lysis buffer/g of cells (25 mM HEPES pH 7.5, 150 mM NaCl) and sonicated. The
resulting cell lysates were centrifuged for 30 min at 17,000 rpm and the supernatant
was discarded. The pellet fraction containing HexaHis Banf1 was resuspended in
solubilisation buffer (25 mM HEPES pH 7.5, 150 mM NaCl, 25 mM imidazole)
containing 6 M guanidinium chloride, and kept for 1 h at 4 °C, under agitation. The
lysate was then centrifuged and the supernatant incubated with HIS-Select® Nickel
Afﬁnity Gel for 2 h at 4 °C, under agitation. The afﬁnity gel was washed with the
solubilisation buffer and the sample was incubated with 10 mM ATP and 5mM
MgCl2 for 20 mins at 4 °C. The protein was eluted from the beads in buffer K
(20 mM KH2PO4, pH 7.4, 0.5 mM EDTA, 10% glycerol, 0.01% IGEPAL) com-
plemented with 300 mM KCl and 250 mM Imidazole. 100 mM DTT was added to
eluents and incubated for 2 h at 40 °C to reduce any remaining disulphide bonds.
A 10 kDa Microsep™ centrifugal device (Pall corporation) was used to
concentrate the puriﬁed protein to a volume of 250 μL. The puriﬁed protein was
then loaded onto a Superose 6 10/300 GL size exclusion chromatography column
(GE healthcare) and run with K buffer containing 300 mM KCl. Fractions
containing monomeric and dimeric Banf1 were pooled, concentrated and stored at
−80 °C.
Puriﬁed histone H3 and H4 were purchased from NEB. For Banf1:PARP1
interactions, 500 ng PARP1 was incubated with 100 ng wild-type or A12T Banf1
for 5 min in PARP1 activity buffer (50 mM Tris-HCl, pH7.8, 10 mM MgCl2 and
1 mM DTT) at room temperature. For experiments where PARP1 was activated
prior to interaction, PARP1 was incubated with 250 μM NAD+, 25 μM
biotinylated NAD+ (Trevigen) and 25 μg double‐stranded activator
oligonucleotide (5′‐GGAATTCC‐3′)40 for 2 min at room temperature. PARP1 was
then immunoprecipitated and immunoblotted using PARP1 antibodies as above.
ADP-Ribose measurement via immunoblotting. Cells were treated with 200 μM
H2O2 for 20 min, then cells were scraped and washed once in phosphate-buffered
saline (PBS), before immediate lysis in either 4× SDS loading dye (diluted to 1X in
lysis buffer following cell lysis) or lysis buffer containing PARG inhibitor (20 mM
Hepes pH7.5, 250 mM KCl, 5% glycerol, 10 mM MgCl2, 0.5% Triton X-100, 1 μΜ
PARG inhibitor (PDD00017273, Sigma), to preserve PAR modiﬁcations. Lysates
were sonicated before being immunoblotted as before.
PARP activity assay. PARP1 was immunoprecipitated from the indicated cell
lines and activity was determined, according to manufacturer’s instructions, by a
Universal Chemiluminescent PARP Assay Kit (Trevigen, # 4676-096-K) based on
HRP-streptavidin-mediated detection of biotin-labelled PAR19. Luminescence was
measured on an EnSpire 2300 Multi-label reader (Perkin Elmer).
Immunoﬂuorescence. Cells were seeded the day before siRNA transfection. Fol-
lowing siRNA transfection cells were allowed to grow for 48–72 h before treatment
or mock-treatment with the indicated DNA damaging agent. Times stated repre-
sent time post removal of DNA damaging agents. After treatment cells were treated
with an extraction buffer, to remove soluble proteins to enable study of chromatin-
bound proteins41 for 5 min before ﬁxation in 4% PFA. Cells were permeabilised
with 0.2% Triton X-100 for 5 min and blocked in 3% bovine serum albumin for
30min. Cells were incubated with indicated primary antibodies and Alexa-
conjugated secondary antibodies for 1 h each at room temperature. Cells were
stained with DAPI, before imaging on a Delta Vision PDV microscope, 60×/1.42 or
100×/1.42 Oil objective (Applied Precision, Inc.). All immunoﬂuorescence ﬁgures
were assembled using ImageJ. High content imaging was performed using the InCell
Analyser 2200 Imaging System (GE Healthcare Life Sciences). Nuclear staining
intensity was analysed using the InCell Investigator software (GE Healthcare Life
Sciences) with a minimum of 500 nuclei quantiﬁed per each independent experi-
ment and the results shown represent the mean and S.D. of three independent
experiments. The protein distribution across the cell was measured using ImageJ
histogram feature. The average Pearson coefﬁcient, r, was calculated from the
analysis of 10 cells in each condition using the Image J Coloc 2 analysis software.
Nuclear envelope quantiﬁcation. Immunoﬂuorescence was performed as above
using anti-Banf1 and anti-Emerin antibodies and images were taken using the
personal DeltaVision microscope. Images were analysed using ImageJ, creating a
line across the cell and generating histograms (Fig. 1a). To assess the proportion of
cells with Banf1 at the nuclear envelope, cells were treated with the indicated
treatment and 50 cells in each condition were assessed for the localisation of Banf1
using a Delta Vision PDV microscope.
Alkaline comet assay. Cells were lifted immediately following mock or 200 μM
H2O2 treatment and 103 cells were mixed with 0.5% low-melting point agarose
(Bio-Rad) (37 °C in 1× TBE). The cell suspension was spread onto a comet slide
(Trevigen) and immersed in lysis buffer (2.5 M NaCl, 100 mM EDTA, 10 mM Tris
(pH10), 1% Triton X-100) for 30 min at 4 °C. Slides were immersed in Alkaline
Comet Buffer (300 mM NaOH, 1 mM EDTA) for 30 min before electrophoresis in
same buffer at 1 Volt/cm (∼300 mA) for 30 min. Slides were then washed in dH2O
and dried at 45 °C for 30 min. The DNA was stained using SYBR® Green I (Sigma)
(1:10,000) before being dried completely and visualised using a Nikon Eclipse Ti
microscope. Quantitation of comet tail moments was performed on a minimum of
50 cells using ImageJ plugin where the densitometry of the head and tail, as well as
length were measured to calculate the comet tail moment. Assays were performed
using at least three biological repeats. Results are displayed as mean ± S.D.
Subcellular fractionation. To detect binding of proteins to chromatin, subcellular
fractionation was carried out using a Subcellular Protein Fractionation Kit for
Cultured Cells, according to the manufacturer’s instructions (Thermo Fisher
Scientiﬁc).
Protein modelling. Protein–protein docking: Several crystal structures of PARP1
inhibitors based on derivatives of natural compounds, such as nicotinamide ade-
nine dinucleotide (NAD+) are available, however, there is no crystal structure of
the complex of the complex of human PARP1 with NAD+. Molecular modelling
study and crystal structure of chicken PARP1 with an NAD+ analogue, CARBA-
NAD overlayed with the human sequence (Fig. 3a). The human and chicken
PARP1 NAD+ binding domain structures are 100% identical. This showed the
indicated role of residues Tyr986, His826, Gly863, Lys903, Ser904, Tyr907 and the
residues 883–893 consisting of a loop42,43. These residues were deﬁned as active
site to study interactions between Banf1 and PARP1. The catalytic domain of
PARP1 (pdb code 4DQY; chain C)44 and Banf1 dimer (Pdb code 2BZF)45 were
submitted to a protein–protein docking evaluation using the ClusPro2.0 server46.
This server performs rigid-body docking to sample billions of conformations, a
RMSD clustering method to ﬁnd highly populated low-energy clusters and an
energy minimisation reﬁnement to remove steric clashes. The ﬁgures were gen-
erated with UCSF Chimera47. The molecular interface analysis was performed
using PDBSUM and PDBePISA.
Decoy analysis: The representative structures of the obtained clusters from
Cluspro docking were ranked with CONSRANK48. The interface in the docking
decoys were analysed, visualised and compared by the COCOMAPS49 web tools.
Modelling PARP1 assembly: To provide insight into poly(ADP-ribose) binding
and sites of potential modiﬁcation by PARP-1 and their effect on PARP1–Banf1
complex, we also generated assembly of full-length PARP1. The full-length
PARP1 structure was generated using structures of known domains and CORAL
programme as previously reported in a SAXS study50.
MD simulations of PARP1–Banf1 complex: To test the overall stability of
the docked complex, we performed a 100-ns long MD simulation. MD simulation
was performed using pmemd.cuda in AMBER16 (ref.51) with ff14SB52 force
ﬁeld for the protein complex in presence of TIP3P53 explicit water molecules and
ions with a triclinic box. The closest distance between any atom originally present
in solute and the edge of the periodic box was set to 10 Å. The particle mesh
Ewald54 was used to treat the long-range electrostatic interactions. The nonbonded
interactions were truncated with 10 Å cutoff. Periodic boundary condition was
imposed on the system during the calculation of nonbonded interactions. The
time-step was set at 2 fs and SHAKE was used to constrain the bonds involving
hydrogen atom. Langevin thermostat with the collision frequency 2.0 was applied
to control the temperature at 300 K. First, the system was minimised with protein
constrained to equilibrate the solvent. Second, the system was minimised with
protein backbone constrained to equilibrate the amino acid side chains and the
solvent. To avoid unnecessary structural drift, we restrained protein Cα atom with
10 kcal/mol Å2. Third, protein was released to minimise the whole simulation
system. Fourthly, the system was slowly heated to 300 K, followed by a 10 ns
equilibration of the whole system in an NPT ensemble at an interval of every 10 fs.
Finally, MDCOns55 analysis was carried out on the last 90-ns production run to
study the conservation of inter-residue contacts during a MD simulation.
NAD+ quantiﬁcation. NAD+ quantiﬁcation was conducted using an NAD/
NADH quantiﬁcation kit (BioVision, Milpitas, CA) as per the manufacturer’s
instructions and normalised to soluble protein content.
Biotinylated NAD+-binding assays. U2OS cells were transfected with Flag-
PARP1 E988K. Twenty-four hour after transfection cells were lysed in 150 mM
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NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.5% NP-40, 10 mM Tris HCl,
pH 7.4 supplemented with protease inhibitors cocktail cOmplete tablets (Roche)
and Cell Signalling phosphatase cocktail, followed by sonication. Fifty microlitre of
lysate was added to a Flag M2 96 well plate (Genscript) and incubated at room
temperature for 30 min. Wells were then washed three times in lysis buffer. Totally,
1.2 µg of puriﬁed Banf1 protein was then added to relevant wells for 30 min at
room temperature. Two microlitre of 250 nM biotinylated NAD+ (Trevigen) and
activating DNA oligo was added to the wells for 10 min at room temperature,
followed by 2 washes in lysis buffer, one wash in PBS-0.1% Triton X-100 and one
wash in PBS. Streptavidin-HRP antibody was added (Trevigen 1:500) for 30 min,
followed by one wash in PBS-0.1% Triton X-100 and two washes in PBS. Peroxyglo
reagent was added to each well and the chemo-illuminescence was read on a plate-
reader.
32P-NAD+-binding assays. Puriﬁed PARP1 E988K was incubated with puriﬁed
Banf1 protein for 30 min in PARP1 activity buffer (50 mM Tris (pH 8), 150 mM
KCl, 12 mM NaCl, 2 mM MgCl2, 5 mM DTT, 0.1% Triton X-100. 250 nM 32P-
NAD+ (250 µCi) and activating DNA oligo were added for 5 min. Reactions were
passed through G25 spin columns to remove unbound NAD+ and total counts
were read on a scintillation counter.
Statistical analysis. Histograms represent the average value ±standard error of the
mean. Statistical analysis of the results was made using Prism software (GraphPad).
ANOVAs (one-way and two-way) and t test (two-tailed) were used for statistical
analysis. Data are presented as means and S.D. from at least three independent
experiments (unless otherwise stated). Statistical signiﬁcance is represented by
*P value < 0.05; **P value < 0.01; ***P value < 0.001; ****P value < 0.0001.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data underlying Figs. 1b, d, 2a–d, 3, 4c–h, 5 and Supplementary Figs. 1c–e, 2,
3, 4a, c, d, 6b–f, 7a, c, e, f, 8c, d, f–h, 9a, b, 10 are provided as a Source Data ﬁle. All data
are available from the authors upon reasonable request.
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